No need to stop oestrogen before gender-affirming surgery: study
Transfeminine patients remaining on the hormone do not appear to be at greater risk of VTE, authors report
Transgender women can safely maintain their oestrogen hormone therapy during gender-affirming surgery without an increased risk of venous thromboembolism (VTE), a study shows.
US researchers examined VTE risk associated with suspending versus continuing oestrogen therapy in the perioperative period for gender-affirming surgeries.
They examined data for all transgender and gender non-binary (TGNB) patients who underwent gender-affirming surgery at a hospital in New York between 2015 and 2019.
Altogether, 919 TGNB individuals underwent 1858 surgical procedures representing 1396 unique cases, of which 407 were transfeminine (male to female) patients undergoing primary vaginoplasty surgery at a mean age of 36 years.
